2026-04-17T17:01:02Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/137972025-10-24T10:29:41Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc De Martin, Eleonora author Riveiro-Barciela, Mar author 2025-10-06T12:54:03Z 2025-10-06T12:54:03Z 2025-09 Antibody-drug conjugates; Checkpoint inhibitors; Hepatotoxicity Conjugados anticuerpo-fármaco; Inhibidores de puntos de control; Hepatotoxicidad Conjugats d'anticossos-fàrmacs; Inhibidors de punts de control; Hepatotoxicitat The advent of novel oncological therapies, including immune checkpoint inhibitors, antibody-drug conjugates, and protein kinase inhibitors, has revolutionised cancer treatment by significantly improving patient survival across a range of malignancies. However, these advances have been accompanied by the emergence of new and often unpredictable adverse events, among which hepatotoxicity represents a growing clinical challenge. In this review, we provide a comprehensive synthesis of current knowledge on liver injury associated with these three key classes of oncological agents, with a particular focus on mechanisms of action and hepatotoxicity, clinical presentation, and management strategies. Given the expanding use of these agents, both as monotherapies or in combination regimens, this topic is of pressing relevance to hepatologists and oncologists alike. As combination therapies become increasingly common, the complexity of drug-liver interactions and their implications for patient safety demand greater interdisciplinary awareness and collaboration. This review advocates for a pragmatic approach to the management of drug-induced liver injury in patients with cancer, underscoring the critical need to balance hepatic preservation with the imperative of maintaining oncological efficacy in this uniquely vulnerable population. By addressing an emerging area of clinical importance, we aim to stimulate further research on oncological hepatotoxicity, a phenomenon that is poised to become increasingly prevalent in routine clinical practice. http://hdl.handle.net/11351/13797 Hepatotoxicitat Fetge - Malalties - Tractament Proteïnes quinases - Inhibidors - Ús terapèutic - Efectes secundaris Medicaments antineoplàstics - Ús terapèutic - Efectes secundaris Immunoglobulines - Ús terapèutic - Efectes secundaris DISEASES::Chemically-Induced Disorders::Chemically-Induced Disorders::Poisoning::Chemical and Drug Induced Liver Injury DISEASES::Digestive System Diseases::Liver Diseases CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates Other subheadings::Other subheadings::Other subheadings::/adverse effects CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents Other subheadings::Other subheadings::Other subheadings::/adverse effects ENFERMEDADES::trastornos inducidos químicamente::trastornos inducidos químicamente::intoxicación::trastornos hepáticos provocados por fármacos y productos químicos ENFERMEDADES::enfermedades del sistema digestivo::enfermedades hepáticas COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos Navigating liver toxicity in the age of novel oncological agents